BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results for Q3 2026 on Thursday, October 29th. The company reported earnings of -$0.42 per share, beating estimates of -$0.60 by $0.18. The company also reported revenue of $353,170,000, beating estimates of $291,206,827 by $61,963,173.
Stock price change since market close: -1.17%
You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BRIDGEBIO PHARMA Insider Trading Activity
BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 43 times in the past 6 months. Of those trades, 0 have been purchases and 43 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- JENNIFER E. COOK has made 0 purchases and 6 sales selling 278,192 shares for an estimated $21,920,434.
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 28 sales selling 161,083 shares for an estimated $11,643,908.
- ANDREA ELLIS sold 17,167 shares for an estimated $1,442,028
- RANDAL W. SCOTT has made 0 purchases and 4 sales selling 10,000 shares for an estimated $671,455.
- HANNAH VALANTINE has made 0 purchases and 2 sales selling 5,004 shares for an estimated $341,523.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $303,280.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BRIDGEBIO PHARMA Hedge Fund Activity
We have seen 250 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 222 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,920,601 shares (-27.6%) from their portfolio in Q2 2026, for an estimated $292,006,362
- WELLINGTON MANAGEMENT GROUP LLP added 2,824,971 shares (+113.7%) to their portfolio in Q2 2026, for an estimated $210,403,840
- JPMORGAN CHASE & CO added 2,397,995 shares (+inf%) to their portfolio in Q2 2026, for an estimated $178,602,667
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,075,272 shares (-54.6%) from their portfolio in Q2 2026, for an estimated $154,566,258
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,900,000 shares (-55.1%) from their portfolio in Q2 2026, for an estimated $141,512,000
- VIKING GLOBAL INVESTORS LP removed 1,893,215 shares (-16.0%) from their portfolio in Q2 2026, for an estimated $141,006,653
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,709,417 shares (+inf%) to their portfolio in Q2 2026, for an estimated $127,317,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BRIDGEBIO PHARMA Congressional Stock Trading
Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 05/11 and 1 sale worth up to $15,000 on 09/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
BRIDGEBIO PHARMA Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 6 analysts offer price targets for $BBIO in the last 6 months, with a median target of $101.0.
Here are some recent targets:
- Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
- Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
- Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
- Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.